검색어 : 통합검색[Columbus Chris]
총 623건 중 623건 출력
, 4/63 페이지
-
31
- Water-Injection Techniques Increase Recovery in Conventional Gas Reservoirs
- Carpenter, Chris; JPT Technology Editor; (JPT : Journal of petroleum technology : official publication of the Society of Petroleum Engineers of AIME, v.70, 2018, pp.87-88)
-
32
- Reputation and Socio-Ecology in Humans
- Romano Angelo; Giardini Francesca; Columbus Simon; de Kwaadsteniet Erik Willem; Kisfalusi Dorottya; Triki Zegni; Snijders Chris; Hagel Kristin; ; (, v., 2021, )
-
33
- Structure–Activity Relationship Studies Using Natural and Synthetic Okadaic Acid/Dinophysistoxin Toxins
- Twiner, Michael J.; Doucette, Gregory J.; Pang, Yucheng; Fang, Chao; Forsyth, Craig J.; Miles, Christopher O.; School of Medicine, Wayne State University, Detroit, MI 48201, USA; Marine Biotoxins Program, Center for Coastal Environmental Health and Biomolecular Research, NOAA/National Ocean Service, Charleston, SC 29412, USA; greg.doucette@noaa.gov; Department of Chemistry, The Ohio State University, Columbus, OH 43220, USA; yucheng.pang@bioduro.com (Y.P.); chaofangphd@yahoo.com (C.F.); forsyth@chemistry.ohio-state.edu (C.J.F.); Department of Chemistry, The Ohio State University, Columbus, OH 43220, USA; yucheng.pang@bioduro.com (Y.P.); chaofangphd@yahoo.com (C.F.); forsyth@chemistry.ohio-state.edu (C.J.F.); Department of Chemistry, The Ohio State University, Columbus, OH 43220, USA; yucheng.pang@bioduro.com (Y.P.); chaofangphd@yahoo.com (C.F.); forsyth@chemistry.ohio-state.edu (C.J.F.); Section for Chemistry and Toxicology, Norwegian Veterinary Institute, Oslo 0454, Norway; chris.miles@vetinst.no; (Marine drugs, v.14, 2016, pp.207)
-
34
- A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus
- Vardas, Eftyhia; Kaleebu, Pontiano; Bekker, Linda-Gail; Hoosen, Anwar; Chomba, Elwyn; Johnson, Philip R.; Anklesaria, Pervin; Birungi, Josephine; Barin, Burc; Boaz, Mark; Cox, Josephine; Lehrman, Jennifer; Stevens, Gwynn; Gilmour, Jill; Tarragona, Tony; Hayes, Peter; Lowenbein, Sarah; Kizito, Eva; Fast, Patricia; Heald, Alison E.; Schmidt, Claudia; Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa.; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI) HIV Vaccine Program, Entebbe, Uganda.; Desmond Tutu HIV Centre, Cape Town, South Africa.; Department of Medical Microbiology, Medunsa, Pretoria, South Africa.; Zambia Emory HIV Research Program, Lusaka, Zambia.; The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 and Columbus Children's Research Institute, Columbus, Ohio.; Targeted Genetics Corporation, Seattle, Washington.; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI) HIV Vaccine Program, Entebbe, Uganda.; The EMMES Corporation, Rockville, Maryland.; International AIDS Vaccine Initiative, Human Immunology Laboratory, Imperial College, London, UK.; International AIDS Vaccine Initiative, New York, New York.; International AIDS Vaccine Initiative, New York, New York.; IAVI Southern Africa Regional Office; (AIDS research and human retroviruses, v.26, 2010, pp.933-942)
-
35
- Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update
- Dowlati, Afshin; Hummel, Horst-Dieter; Champiat, Stephane; Olmedo, Maria Eugenia; Boyer, Michael; He, Kai; Steeghs, Neeltje; Izumi, Hiroki; Johnson, Melissa L.; Yoshida, Tatsuya; Bouchaab, Hasna; Borghaei, Hossein; Felip, Enriqueta; Jost, Philipp J.; Gadgeel, Shirish; Chen, Xi; Yu, Youfei; Martinez, Pablo; Parkes, Amanda; Paz-Ares, Luis; University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH; Translational Oncology/Early Clinical Trial Unit (ECTU), Bavarian Cancer Research Center, National Center for Tumor Diseases, Comprehensive Cancer Center Mainfranken and University Hospital Wü rzburg, Wü rzburg, Germany; Department of Therapeutic Innovation and Early Phase Trials, Gustave Roussy, Villejuif, France; Department of Medical Oncology, Ramó n y Cajal University Hospital, Madrid, Spain; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia; Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, OH; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Department of Thor; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.42, 2024, pp.3392-3399)
-
36
- Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.
- Marabelle, Aurelien; Cassier, Philippe Alexandre; Fakih, Marwan; Guren, Tormod Kyrre; Italiano, Antoine; Kao, Steven Chuan-Hao; Nielsen, Dorte; Ascierto, Paolo Antonio; Bariani, Giovanni M.; Santoro, Armando; Shah, Manisha H.; Asselah, Jamil; El-Khoueiry, Anthony B.; Spencer, Kristen Renee; Takahashi, Shunji; Chatterjee, Arkendu; Jin, Fan; Norwood, Kevin; Delord, Jean-Pierre; Gustave Roussy, INSERM U1015, Villejuif, France; ; Centre Lé on Bé rard, Lyon, France; ; City of Hope National Medical Center, Duarte, CA; ; Department of Oncology, Oslo University Hospital, Oslo, Norway; ; Institut Bergonié , Bordeaux, France; ; Chris O’Brien Lifehouse, Camperdown, NSW, Australia; ; Herlev Hospital, University of Copenhagen, Copenhagen, Denmark; ; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy; ; Instituto do Câ ncer do Estado de Sã o Paulo, Universidade de Sã o Paulo, Sã o Paulo, Brazil; ; Humanitas Cancer Center, Humanitas University, Milan, Italy; ; Ohio State University Comprehensive Cancer Center, Columbus, OH; ; McGill University, Montré al, QC, Canada; ; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; ; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; ; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; ; Merc; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.38, 2020, pp.1-1)
-
37
- Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).
- Bendell, Johanna C.; LoRusso, Patricia; Overman, Michael J.; Noonan, Anne M.; Kim, Dong-Wan; Strickler, John; Kim, Sang-We; Clarke, Stephen John; George, Thomas J.; Grimison, Peter S.; Barve, Minal A.; Amin, Manik A.; Desai, Jayesh; Wise-Draper, Trisha; Cooper, Zachary; Elgeioushi, Nairouz; Mueller, Nancy Kathryn; Kumar, Rakesh; Wu, Kevin YuFeng; Patel, Sandip Pravin; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; ; Yale University Cancer Center, New Haven, CT; ; MD Anderson Cancer Center, Houston, TX; ; The Ohio State University Wexner Medical Center, Columbus, OH; ; Seoul National University Hospital, Seoul, South Korea; ; Duke University Medical Center, Durham, NC; ; Asan Medical Center, Seoul, South Korea; ; Royal North Shore Hospital, St. Leonards, Australia; ; University of Florida/UF Health Cancer Center, Gainesville, FL; ; Chris O'Brien Lifehouse, Sydney, NSW, Australia; ; Mary Crowley Cancer Research Center, Dallas, TX; ; Washington University School of Medicine, St. Louis, MO; ; Royal Melbourne Hospital, Parkville, VIC, Australia; ; University of Cincinnati Medical Center, Cincinnati, OH; ; AstraZeneca, Gaithersburg, MD; ; AstraZeneca, Gaithersburg, MD; ; AstraZeneca, Gaithersburg, MD; ; AstraZeneca, Gaithersburg, MD; ; AstraZeneca, Gaithersburg, MD; ; Moores Cancer Center, La Jolla, CA; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.39, 2021, pp.9047-9047)
-
38
- Efficacy of Chlorantraniliprole in Controlling Structural Infestations of the Eastern Subterranean Termite in the USA
- Jones, Susan C.; Vargo, Edward L.; Keefer, T. Chris; Labadie, Paul; Scherer, Clay W.; Gallagher, Nicola T.; Gold, Roger E.; Department of Entomology, The Ohio State University, Columbus, OH 43210, USA; Department of Entomology, Texas A&M University, College Station, TX 77843, USA; ed.vargo@tamu.edu (E.L.V.); r-gold@tamu.edu (R.E.G.); Department of Entomology, Texas A&M University, College Station, TX 77843, USA; ed.vargo@tamu.edu (E.L.V.); r-gold@tamu.edu (R.E.G.); Department of Entomology, North Carolina State University, Raleigh, NC 27695, USA; paul_labadie@ncsu.edu; Syngenta AG, 4002 Basel, Switzerland; clay.scherer@syngenta.com; Syngenta Crop Protection, LLC, Greensboro, NC 27409, USA; chris.keefer@syngenta.com (T.C.K.); nicky.gallagher@syngenta.com (N.T.G.); Department of Entomology, Texas A&M University, College Station, TX 77843, USA; ed.vargo@tamu.edu (E.L.V.); r-gold@tamu.edu (R.E.G.); (Insects, v.8, 2017, pp.92)
-
39
- ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- Johnson, Bruce E.; Kabbinavar, Fairooz; Fehrenbacher, Louis; Hainsworth, John; Kasubhai, Saifuddin; Kressel, Bruce; Lin, Chin-Yu; Marsland, Thomas; Patel, Taral; Polikoff, Jonathan; Rubin, Mark; White, Leonard; Yang, James Chih-Hsin; Bowden, Chris; Miller, Vincent; Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA; Fairooz Kabbinavar, University of California Los Angeles, Translational Oncology Research International, Los Angeles; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo; Chin-Yu Lin and Chris Bowden, Genentech, South San Francisco; Jonathan Polikoff, Southern California Permanente Medical Group, San Diego, CA; John Hainsworth, Sarah Cannon Research Institute, Nashville, TN; Saifuddin Kasubhai, Northwest Medical Specialties, Tacoma, WA; Bruce Kressel, Sibley Memorial Hospital, Washington, DC; Thomas Marsland, Integrated Community Oncology Network, Orange Park; Mark Rubin, Florida Cancer Specialists, Fort Myers, FL; Taral Patel, The Mark H. Zangmeister Center, Columbus, OH; Leonard White, Arch Medical Services, The Center for Cancer Care and Research, Saint Louis, MO; Vincent Miller, Weill Cornell Medical College and Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; and James Chih-H; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.31, 2013, pp.3926-3934)
-
40
- Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
- Overman, Michael J.; LoRusso, Patricia; Strickler, John H.; Patel, Sandip Pravin; Clarke, Stephen John; Noonan, Anne M.; Prasanna, Thiru; Amin, Manik A.; Nemunaitis, John J.; Desai, Jayesh; O'Byrne, Kenneth John; George, Thomas J.; Englert, Judson; She, Dewei; Cooper, Zachary A.; Wu, Yuling; Khan, Anis; Kumar, Rakesh; Bendell, Johanna C.; The University of Texas MD Anderson Cancer Center, Houston, TX; ; Yale University Cancer Center, New Haven, CT; ; Duke Comprehensive Cancer Center-Duke Cancer Institute Duke University Health System, Durham, NC; ; Moores Cancer Center, University of California, San Diego, La Jolla, CA; ; Royal North Shore Hospital, St Leonards, NSW, Australia; ; 6Arthur G. James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus, OH; ; Chris O'Brien Lifehouse, Camperdown NSW, Australia; ; Washington University School of Medicine, St. Louis, MO; ; University of Toledo College of Medicine and Life Sciences, Toledo, OH; ; Royal Melbourne Hospital, Parkville Victoria, Australia; ; Princess Alexandra Hospital Brisbane, Queensland, Australia; ; University of Florida, Health Cancer Center, Gainesville, FL; ; MedImmune, Gaithersburg, MD; ; MedImmune, LLC, Gaithersburg, MD; ; MedImmune, LLC, Gaithersburg, MD; ; MedImmune, LLC, Gaithersburg, MD; ; MedImmune; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.36, 2018, pp.4123-4123)
QUICK MENU
